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Carotid-femoral pulse wave velocity (cfPWV) by direct measurement with tonometry is the 
gold standard means for assessing aortic stiffness and is associated with adverse cardiovascular 
disease (CVD) outcomes.1 Equations using age and mean blood pressure (BP) may be useful 
to estimate PWV (ePWV) 2 and have been shown to predict all-cause and CVD mortality in 
individuals with hypertension,3 but its predictive capacity for CVD outcomes has yet to be 
tested more broadly in the general population. The purpose of this study was to evaluate 
whether ePWV would be associated with CVD outcomes and mortality. 
   This prospective study was based on the general population sample of 2,666 middle-aged 
Caucasian men (aged mean SD 53.1±5.1, range 42-61 years) in the Kuopio Ischemic Heart 
Disease cohort study. ePWV was calculated from an equation based on age and mean blood 
pressure (MBP).2,3 Levels of ePWV were categorized according to quartiles (<8.5 [the lowest], 
8.5-9.2, 9.2-10.0, and >10.0 m/s [the highest]).2,5 Cardiovascular outcomes were operationally 
defined as cardiovascular mortality (CVM), sudden cardiac death (SCD) and atrial fibrillation 
(AF). All-cause mortality (ACM) was also assessed. We used Cox proportional hazard adjusted 
models to determine the hazard ratios (HRs) and 95% confidence intervals (CIs) of ePWV for 
outcomes. To further evaluated whether ePWV would be associated with an improvement in 
the prediction of CVM risk using the Systematic Coronary Risk Evaluation (SCORE) 
algorithm (comprising of age, sex, smoking status, SBP, total cholesterol, and HDL-C ) and 
the Framingham CVD Risk Score (FRS) (comprising of age, sex, smoking status, SBP, total 
cholesterol, HDL-C and diabetes status), we calculated measures of discrimination (using 
Harrell’s C-index and difference in -2 log likelihood) and reclassification (using net-
reclassification-index, NRI and integrated-discrimination-improvement, IDI).4 
   During a median 25-year follow-up (interquartile ranges: 18-27 years), 1,274 ACM, 594 
CVM, 255 SCD, and 511 AF events occurred, respectively. Cumulative hazard curves 
 3 
 
demonstrated lower survival among males of ePWV value > 10.0 m/s compared to those of 
ePWV value < 10.0 m/s (P<0.001 for log-rank test; Figure 1).  
   After adjusting for CVD risk factors (Table 1), the highest levels of ePWV were 
significantly associated with an increased risk for ACM (hazard ratio [HR] 1.39, 95% 
Confidence Interval [CI]: 1.11-1.73), CVM (HR 1.79, 95% CI, 1.27-2.52), SCD (HR 1.86, 95% 
CI, 1.11-3.11), and AF (HR 1.46, 95% CI, 1.03-2.06), as compared with the lowest level of 
ePWV (reference). On addition of ePWV to SCORE, there was no significant increase in the 
C-index: -0.0001 (95% CI: -0.0012, 0.0010; p=0.82) and no significant improvement in the -2 
log likelihood of the risk score with and without inclusion of ePWV (p for comparison=0.48). 
There was no significant improvement in the classification of participants into predicted 10-
year CVM risk categories (NRI: 0.26%, -2.88, 3.40%; p=0.87). The IDI was -0.0001 (-0.0007, 
0.0004; p = 0.62). For the FRS, the C-index change; -2 log likelihood p-value for comparison; 
NRI; and IDI were 0.0002 (95% CI: -0.0012, 0.0016; p=0.77); p for comparison=0.31; 1.03%, 
-1.57, 3.63%; p=0.44); and -0.0001 (-0.0010, 0.0007; p = 0.78) respectively. 
   These findings demonstrate that ePWV is related to CVD outcomes and mortality, 
independent of traditional CVD risk factors, in the general population. Individuals having an 
ePWV value > 10.0 m/s 5 were 79% more likely to die from CVD, 86% more likely to die from 
SCD and 46% more likely to suffer from AF compared to those with lower ePWV (<8.5 m/s). 
Our findings support the importance of elevated arterial stiffness as independently associated 
with AF risk6 and add to the novel observation that elevated levels of arterial stiffness may also 
be associated with SCD risk. However, addition of ePWV to contemporary CVD risk scores 
such as SCORE and the FRS, did not improve discrimination of CVD mortality risk. A 
limitation of this study is that the cohort examined was exclusively men. Additional research 
examining the role of ePWV as a predictor of CVD events in women is warranted. These 
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findings demonstrate a potential role of arterial stiffness in identifying patients at high risk for 
adverse cardiovascular outcomes, but further evaluation is warranted in differing populations 
(general population vs. hypertensive) and racial/ethnic backgrounds. Finally, it should be 
evaluated whether ePWV (like cfPWV) is similarly and favorably modulated by different 
lifestyle and rehabilitation modalities such as exercise and sauna bathing7.    
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Table 1. The hazard ratio and 95% confidence interval for all-cause mortality, cardiovascular 
mortality, sudden cardiac death, and atrial fibrillation by ePWV quartiles (n=2,666).  
ePWV < 8.5 m/s 
(n=637) 
8.5-9.2 m/s 
(n=643) 
9.2-10.0 m/s 
(n=694) 
>10.0 m/s 
(n=692) 
All-cause 
mortality  
1 (ref) 0.99 
(0.80-1.22) 
1.27 
(1.03-1.57) 
1.39 
(1.11-1.73) 
Cardiovascular 
mortality 
1 (ref) 1.01 
(0.79-1.54) 
1.58  
(1.13-2.19) 
1.79 
 (1.27-2.52) 
Sudden cardiac 
death 
1 (ref) 1.11 
 (0.67-1.83) 
1.57  
(0.95-2.59) 
1.86  
(1.11-3.11) 
Atrial  
fibrillation 
1 (ref) 1.04 
 (0.76-1.44) 
1.10 
 (0.79-1.53) 
1.46  
(1.03-2.06) 
Adjusted for age, body mass index, smoking, diabetes, anti-hypertensive medication, total 
cholesterol, HDL-C, glucose, C-reactive protein, CVD history, alcohol intake, maximal oxygen 
uptake and family history of CVD. ePWV: estimated pulse wave velocity 
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Figure 1. The cumulative hazard curves for all-cause mortality and cardiovascular mortality by ePWV value > 10.0 m/s.  
 
 
 
20
30
40
50
60
70
80
90
100
All-cause mortality
0 5 10 15 20 25 30
Follow-up time (years)
S
u
rv
iv
a
l p
ro
b
a
b
ili
ty
 (
%
)
ePWV
< 10 m/sec
> 10 m/sec
40
50
60
70
80
90
100
CVD mortality
0 5 10 15 20 25 30
Follow-up time (years)
S
u
rv
iv
a
l 
p
ro
b
a
b
ili
ty
 (
%
)
ePWV
< 10 m/sec
> 10 m/sec
